anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In numerous countries, the utilization of plants for both nutritional and therapeutic purposes is a common practice. However, the inadvertent use of these plants can pose risks due to their active molecules or microbiota. The traditional use of Herniaria glabra L. (H. glabra) plant in treating various diseases is well-known; however, its application in yogurt production raises concerns. In this study, Bacillus pumilus isolated from H. glabra was identified through 16s rRNA sequencing and MALDI-TOF MS (Matriks Assisted Lazer Desorption Ionization Time of Flight Massspectrometry). The bacterium's resistance under simulated gastrointestinal tract (GIT) conditions was assessed, followed by investigations into its aggregation ability, antibiotic resistance, hemolytic activity, and antagonistic potential through in vitro tests. The study revealed that B. pumilus exhibited 100% resistance to GIT conditions. Notably, the bacterium demonstrated strong autoaggregation (34.48%) and coaggregation abilities (49.82% for Escherichia coli, 49.13% for Listeria monocytogenes), signifying a potent aggregative potential. Sensitivity to most tested antibiotics was observed, while no antagonistic activity against tested bacteria was evident. Furthermore, the bacterium exhibited β-hemolytic activity, indicative of potential virulence. The findings suggest that this resistant yet virulent bacterium, with its hemolytic activity, could disrupt the GIT balance, posing serious health risks. The study underscores the need for caution and awareness regarding the potential dangers posed by bacteria in plant microbiota in herbal therapies.
The method involves seizing keywords regarding a medical issue (F) and automatic decoding of the seized keywords into search criteria (K) under access to a rule database (RDB). Medical data records are searched in the data base (DB) on the basis of search criteria. The search results (E) are seized, and send in a configurable state to a selectable presentation entity for presentation, by which the data base is analyzed e.g. by a statistical evaluation. The analysis rules are derived and are stored in the rule database on the basis of statistical evaluation. Independent claims are also included for the following: (1) a medical information system or a sanitary telematics system has a data base (2) a device for search of medical data records in a hospital information system or in a sanitary telematics system has a data base for the storage of medical data records.
This project proposes an intervention program for dementia prevention based on the Taiwanese model. The investigator(s) will screen the elderly who are not yet demented but are at high risk of dementia and will randomly allocate them into three groups (on site intervention group, remote intervention group, and control group) for a two-year multi-modal non-pharmacological intervention. All intervention groups will be actively involved in management with nutrition, exercise and cognitive programs. The on-site intervention group requires subjects to participate in prescribed place according to the protocol. The remote intervention group is designed for reducing the chances of person-to-person contact response to the current coronavirus disease 2019 (COVID-19) pandemic and development of digital internet. It uses innovative technology combining wearable devices with inertial measurement units, blue-tooth equipment, apps, feedback technology and artificial intelligence based remote comprehensive training programs. During the study period, each group will be regularly monitored the changes of cardiovascular risk factors, physical performance and cognitive function. The results of multimodal intervention mainly from Taipei and New Taipei City will establish the Taiwan FINGER model (TaiPEI) and will have the information of the conditions and feasibility achieved in Taiwan and implementation suggestions in the face of the epidemic. It can be subsequently applied to the brain/body health care institution and to the prevention of dementia and cardiovascular disease of elderly.
Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
Neuroinflammation is a recognized complication of immunotherapeutic approaches such as immune checkpoint inhibitor treatment, chimeric antigen receptor therapy, and graft versus host disease (GVHD) occurring after allogeneic hematopoietic stem cell transplantation. While T cells and inflammatory cytokines play a role in this process, the precise interplay between the adaptive and innate arms of the immune system that propagates inflammation in the central nervous system remains incompletely understood. Using a murine model of GVHD, we demonstrate that type 2 cannabinoid receptor (CB2R) signaling plays a critical role in the pathophysiology of neuroinflammation. In these studies, we identify that CB2R expression on microglial cells induces an activated inflammatory phenotype that potentiates the accumulation of donor-derived proinflammatory T cells, regulates chemokine gene regulatory networks, and promotes neuronal cell death. Pharmacological targeting of this receptor with a brain penetrant CB2R inverse agonist/antagonist selectively reduces neuroinflammation without deleteriously affecting systemic GVHD severity. Thus, these findings delineate a therapeutically targetable neuroinflammatory pathway and have implications for the attenuation of neurotoxicity after GVHD and potentially other T cell-based immunotherapeutic approaches.
CONTEXT: Studies generally focus on one type of chronic condition and the effect of medical cannabis (MC) on symptoms; little is known about the perceptions and engagement of patients living with chronic conditions regarding the use of MC.
OBJECTIVES: This scoping review aims to explore: (1) what are the dimensions addressed in studies on MC that deal with patients' perceptions of MC? and (2) how have patients been engaged in developing these studies and their methodologies? Through these objectives, we have identified areas for improving future research.
METHODS: We searched five databases and applied exclusion criteria to select relevant articles. A thematic analysis approach was used to identify the main themes: (1) reasons to use, to stop using or not to use MC, (2) effects of MC on patients themselves and empowerment, (3) perspective and knowledge about MC, and (4) discussion with relatives and healthcare professionals.
RESULTS: Of 53 articles, the main interest when assessing the perceptions of MC is to identify the reasons to use MC (n = 39), while few articles focused on the reasons leading to stop using MC (n = 13). The majority (85%) appraise the effects of MC as perceived by patients. Less than one third assessed patients' sense of empowerment. Articles determining the beliefs surrounding and knowledge of MC (n = 41) generally addressed the concerns about or the comfort level with respect to using MC. Only six articles assessed patients' stereotypes regarding cannabis. Concerns about stigma constituted the main topic while assessing relationships with relatives. Some articles included patients in the research, but none of them had co-created the data collection tool with patients.
CONCLUSIONS: Our review outlined that few studies considered chronic diseases as a whole and that few patients are involved in the co-construction of data collection tools as well. There is an evidence gap concerning the results in terms of methodological quality when engaging patients in their design. Future research should evaluate why cannabis' effectiveness varies between patients, and how access affects the decision to use or not to use MC, particularly regarding the relationship between patients and healthcare providers. Future research should consider age and gender while assessing perceptions and should take into consideration the legislation status of cannabis as these factors could in fact shape perception. To reduce stigma and stereotypes about MC users, better quality and accessible information on MC should be disseminated.
This study includes a dose escalation phase and a dose expansion phase. The dose escalation phase will adopt a 3+3 design. Subjects were first treated with BioTTT001 monotherapy (hepatic artery infusion, administered every 2 weeks, D1 and D15 for a total of two doses) after enrollment. If the subject does not develop dose-limiting toxicity (DLT) in the monotherapy stage and is judged to be safe and tolerable by the investigator, the subject will enter the treatment phase of BioTTT001 in combination with toripalimab and regorafenib( toripalimab 80mg iv. D1 and D15 , BioTTT001 5×10\^7 viral particle (VP)/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic arterial infusion (HAI.) D2 and D16 , regorafenib 80 mg Po. D1-D21; 4 weeks per cycle), and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase. In the dose expansion phase, different dose groups can be expanded, and the total number of enrolled subjects is expected to be 30 for further safety, tolerability, pharmacokinetics and preliminary efficacy evaluation.
The invention relates to an alpaca source nano antibody and application thereof, in particular to an alpaca source nano antibody R211 combined with SARS-CoV-2RBD or an antigen combination fragment thereof and application thereof, wherein the antibody comprises a heavy chain variable region which comprises the following CDRs: CDR1 with an amino acid sequence shown as SEQ ID NO. 1, CDR2 with an amino acid sequence shown as SEQ ID NO. 2 and CDR3 with an amino acid sequence shown as SEQ ID NO. 3. The nano antibody R211 can be combined with SARS-CoV-2RBD protein with higher affinity, and can neutralize SARS-CoV-2 original strain and a series of variant strains thereof with higher neutralization activity, thereby inhibiting the infection thereof. The nano antibody R211 has huge potential application value in the aspects of clinical treatment, prevention and/or detection of SARS-CoV-2 original strain, variant strain thereof and related coronavirus infection.
BACKGROUND: Lower urinary tract symptoms (LUTS) are highly prevalent and very bothersome. To support the best possible allocation of health care resources and to avoid unnecessary expenditures, it is important to understand and quantify the wide-ranging health care costs affecting people suffering from LUTS. We aimed at creating a foundation for exploring the cost of LUTS.
METHOD: In this systematic literature review, we explored the costs of illness of the LUTS umbrella. We used the online literature review tool Silvi.ai for transparent decision-making and literature management.
RESULTS: A total of 1821 original articles were screened. Forty had explored the cost of illness of a LUTS disease since 2013. The studies were conducted in 18 countries. A number of different study designs were applied, including both retrospective and prospective studies. In total, seven LUTS indications were explored. None of them focused on lifelong LUTS. None of them were conducted in infants or children. Eighty-two percent were conducted in adults and 18% in frail elderly. Most cost of illness studies focused on the cost of hospitalization and use of medicine.
CONCLUSION: We have created the groundwork for understanding the cost of LUTS illness. To fully understand the cost of illness of lifelong LUTS, the main gap in research is to investigate the cost of LUTS in infants and children.
Somatic Y chromosome loss in hematopoietic cells is associated with higher mortality in men. However, the status of the Y chromosome in cancer tissue is not fully known due to technical limitations, such as difficulties in labelling and sequencing DNA from the Y chromosome. We have developed a system to quantify Y chromosome gain or loss in patient-derived prostate cancer organoids. Using our system, we observed Y chromosome loss in 4 of the 13 (31%) patient-derived metastatic castration-resistant prostate cancer (mCRPC) organoids; interestingly, loss of Yq (long arm of the Y chromosome) was seen in 38% of patient-derived organoids. Additionally, potential associations were observed between mCRPC and Y chromosome nullisomy. The prevalence of Y chromosome loss was similar in primary and metastatic tissue, suggesting that Y chromosome loss is an early event in prostate cancer evolution and may not a result of drug resistance or organoid derivation. This study reports quantification of Y chromosome loss and gain in primary and metastatic prostate cancer tissue and lays the groundwork for further studies investigating the clinical relevance of Y chromosome loss or gain in mCRPC.
Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
Light-therapy with filters that reduced lamp output to less than 50 lux. for 30 minutes as soon as possible after awakening.
Arthroscopic management of hip femoroacetabular impingement shows reliable improvement in pain and patient-reported outcomes, high survivorship, and low conversion to total hip arthroplasty, particularly in the absence of dysplasia. Concomitant labral repair-or augmentation versus reconstruction when indicated- consistently shows better results than labral debridement. The effect of labral size on outcomes has been studies in several series. Some studies show that smaller labra show inferior outcomes after repair, others show labral size makes no difference in outcomes, and one showed that patients large labra actually had worse outcomes. Perhaps labral size at either extreme does worse. Labral size is likely to remain one of many factors worth evaluating when prognosticating repair outcomes or indicating when advanced reconstructive options are warranted.
A surgical instrument comprising a shaft, an end effector, a housing, a drive assembly, and a manually-driven actuator is disclosed. The end effector comprises a first jaw and a second jaw rotatable relative to the first jaw between an open position and a clamped position. The housing comprises a rotary input movable by a motor. The drive assembly is operably engaged with the rotary input. The drive assembly is movable by the motor in a motorized mode of operation to transition the second jaw toward the clamped position. The drive assembly is movable in a non-motorized mode of operation by the manually-driven actuator to permit a transition of the second jaw toward the open position to release tissue between the first jaw and the second jaw.
PURPOSE: A composition containing a compound or pharmaceutically acceptable salt thereof is provided to maintain or stabilize membrane potential. CONSTITUTION: A composition for treating mitochondrial diseases contains a compound of chemical formula I or pharmaceutically acceptable salt thereof as an active ingredient. The compound of chemical formula I is (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin(BH4). The composition is used by oral administration, rectal administration, or parenteral administration. The composition further contains a carrier of excipient, binder, and disintegrant. The excipient is selected from starch, lactose, saccharose, mannitol, and cellulose.
FIELD: medicine, oncology. SUBSTANCE: invention proposes the surgery method to minimize the volume of malignant mass in combination with intramuscular administration of a mixture of native DNA and anthracycline antibiotic. The mixture has 5 mg of anthracycline antibiotic dissolved in 4 ml of solvent, 75 mg of DNA and 2 ml of 0.5% novocaine solution. The total dose of anthracycline antibiotic is 50 mg for course of treatment. Invention proposes to use an activation of antitumor cells of the host-body (CD-16) by extracorporal pig spleen connecting. EFFECT: enhanced effectiveness of treatment. 5 ex
FIELD: medicine, radiodiagnosis. SUBSTANCE: invention relates to radioactive immunoreagent exhibiting the directed effect that is a conjugate of a chelating agent and immunoreactive group labeled with radioactive metal ion. Ion of radioactive metal has an atomic number from 21 to 84. Immunoreactive group is an antibody, oligonucleotide or polypeptide. Chelating agent is a derivative of tripyridine. Invention gives the total formula of a chelating agent used. A composition for obtaining an image of malignant neoplasm in body containing a contrasting radioactive agent of the above indicated composition at effective amount and pharmaceutically acceptable diluting agent is described also. Invention relates to also a method of obtaining an image of malignant neoplasm. Method is carried out by administration to patient a composition containing radioactive label that involves a chelate at effective amount. Radiation intensity produced by radioactive label is measured for time that is necessary for antibody accumulation on neoplasm site. Radiation intensity is determined using the special device for photoscanning. Invention gives also a chelating agent that is a component of immunoreactive of the directed effect that is a tripyridine derivative. Proposed immunoreagents do not metabolize and harmful dispersing, show less radiotoxicity as compared with yttrium-containing radioactive immunoreagents obtained with other chelating agents. EFFECT: improved method of an image obtaining, improved quality of composition. 12 cl, 7 dwg, 20 ex
Robust and sensitive clinical measures are needed for more accurate and earlier detection of Alzheimer's disease (AD), for staging preclinical AD, and for gauging the efficacy of treatments. Mild impairment on episodic memory tests is thought to indicate a cognitive risk of developing AD and mild cognitive impairment (MCI), considered to be a transitional stage between normal aging and AD. Novel tests of semantic memory, such as memory for news events, are also impaired early on but have received little clinical attention even though they may provide a novel way to assess cognitive risk for AD. We examined memory for news events in older adults with normal cognition (NC, N = 34), amnestic MCI (aMCI, N = 27), or non-aMCI (N = 10) using the Retrograde Memory News Events Test (RM-NET). We asked if news event memory was sensitive to 1) aMCI and also non-aMCI, which has rarely been examined, 2) genetic risk for dementia (positive family history of any type of dementia, presence of an APOE-4 allele, or polygenic risk for AD), and 3) subjective memory functioning judgments about the past. We found that both MCI subgroups exhibited impaired RM-NET Lifespan accuracy scores together with temporally-limited retrograde amnesia. For the aMCI group amnesia extended back 45 years prior to testing, but not beyond that time frame. The extent of retrograde amnesia could not be reliably estimated in the small non-aMCI group. The effect sizes of having MCI on the RM-NET were medium for the non-aMCI group and large for the aMCI group, whereas the effect sizes of participant characteristics on RM-NET accuracy scores were small. For the combined MCI group (N = 37), news event memory was significantly related to positive family history of dementia but was not related to the more specific genetic markers of AD risk. For the NC group, news event memory was not related to any measure of genetic risk. Objective measures of past memory from the RM-NET were not related to subjective memory judgements about the present or the recent past in either group. By contrast, when individuals subjectively compared their present versus past memory abilities, there was a significant association between this judgment and objective measures of the past from the RM-NET (direct association for the NC group and inverse for the MCI group). The RM-NET holds significant promise for early identification of those with cognitive and genetic risk factors for AD and non-AD dementias.
Participation in activities is an essential component of maintaining health. The International Classification of Functioning- Child and Youth (ICF-CY) framework includes several components that can be used to determine activity and participation. These components are defined by two terms: capacity and performance. Both capacity and performance are basically measures of capability, even if the performance qualifier is intended as a measure of participation. Performance describes what a person does in their current setting. The current environment brings with it a social context. As a result, performance determines how involved an individual is in his or her living environment and life experience. The ability to do a task or action is known as capacity, which denotes the highest functional level that may be achieved at any moment and in every setting. Capacity is measured in a consistent or standard setting. Therefore, it reflects the individually adjusted ability of the individual. The child's physical and social environment has an impact on their capacity. For instance, while the child can stand up on his own in a standardized clinical setting, he might not be able to do the same after falling during physical exercise in a school context or in public.

According to the ICF-CY, disability is not only related to body structure and function but also to activity constraints and participation restrictions in various situations. An objective assessment demonstrates how performance has changed over time and encourages children to enhance their own abilities. These examinations need to meet psychometric standards before being used with children. In addition, the results of research studies provide useful information about the natural developmental steps expected, especially in childhood disability subgroups. There isn't a valid and reliable scale in Turkish literature that assesses children's capacity and performance in activities at home, school, and in play environments. The goals of our research are to demonstrate the reliability and validity of the ASK, a tool that assesses children's participation and activity levels at play, school, and at home. Families and medical professionals will be guided by this scale.